The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Inactivated Influenza Vaccine Market By 2030 Starting From Its 2026 Size?
The inactivated influenza vaccine market size has experienced significant expansion in recent years. It is projected to grow from $7.14 billion in 2025 to $7.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The upward trend in the historic period can be ascribed to various factors including increasing seasonal influenza incidence, the expansion of immunization programs, a heightened awareness of preventive healthcare, the availability of egg-based vaccine production, and the development of public health initiatives.
The inactivated influenza vaccine market is anticipated to show considerable expansion over the next few years. It is set to reach $10.55 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This growth during the forecast period can be linked to a heightened emphasis on pandemic readiness, increased investments in cell-based and recombinant vaccines, broadened immunization coverage for adults and the elderly, growing government procurement of vaccines, and continuous innovation in vaccine manufacturing technologies. Significant trends expected during this period involve a greater acceptance of quadrivalent influenza vaccines, an increasing concentration on high-dose and adjuvanted vaccine types, the expansion of seasonal vaccination programs, a rising focus on cold-chain optimization, and an enhanced emphasis on vaccine manufacturing scalability.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24251&type=smp
What Primary Drivers Are Shaping The Development Of The Inactivated Influenza Vaccine Market?
The increasing government vaccination initiatives are projected to fuel the growth of the inactivated influenza vaccine market moving forward. These programs are expanding due to rising public health awareness across populations, leading to a greater need for immunization services and encouraging governments to improve vaccine access and outreach efforts. Government vaccination programs support the delivery of inactivated influenza vaccines by offering free or subsidized access to high-risk groups, thereby ensuring fair immunization coverage and lessening the impact of seasonal influenza. For example, in December 2023, the National Health Service, a UK-based government agency, launched an NHS vaccine strategy with immunization targets, including provisions for community-based vaccination services, especially targeting underserved and marginalized groups. Therefore, the expansion of government vaccination programs is a significant factor driving the inactivated influenza vaccine market’s growth.
Which Segment Categories Define The Inactivated Influenza Vaccine Market?
The inactivated influenza vaccine market covered in this report is segmented –
1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV), Quadrivalent Inactivated Influenza Vaccine (QIIV)
2) By Application: Children, Adolescence, Adults, Elderly
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Clinics
4) By End-User: Healthcare Providers, Individuals, Government Organizations, Pharmaceutical Companies
Subsegments:
1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine, Cell-based Trivalent Inactivated Influenza Vaccine, Adjuvanted Trivalent Inactivated Influenza Vaccine, High-dose Trivalent Inactivated Influenza Vaccine
2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine, Cell-based Quadrivalent Inactivated Influenza Vaccine, Adjuvanted Quadrivalent Inactivated Influenza Vaccine, Recombinant Quadrivalent Inactivated Influenza Vaccine, Pediatric Quadrivalent Inactivated Influenza Vaccine
What Major Market Trends Are Driving Changes In The Inactivated Influenza Vaccine Market?
Leading companies operating within the inactivated influenza vaccine market are concentrating on developing quadrivalent inactivated influenza vaccines to provide more extensive protection against four strains of the influenza virus. A quadrivalent inactivated influenza vaccine serves as a flu shot that safeguards against four different flu viruses. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine designed to offer seasonal defense against four new virus strains. VaxiFlu-4 delivers broader protection by covering both influenza A and B strains, thereby reducing the chance of vaccine mismatch. This vaccine aims to tackle seasonal flu outbreaks with an improved immune response customized to regional epidemiological patterns.
Who Are The Top Companies Competing In The Inactivated Influenza Vaccine Market?
Major companies operating in the inactivated influenza vaccine market are Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Viatris Inc., Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Hualan Biological Bacterin Co. Ltd., Changchun Biological Products Co. Ltd., Dalian Aleph Biomedical Co. Ltd., Jiangsu GDK Biotechnology Co. Ltd., KM Biologics Co. Ltd., JoinHub Pharma, Seqirus (CSL Influenza Division), Serum Institute of India Pvt. Ltd., Biological E. Limited, Shenzhen Sanofi Pasteur Biologicals Co. Ltd., Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Sinopharm CNBG, Takeda Pharmaceutical Company Limited, Pfizer
Read the full inactivated influenza vaccine market report here:
https://www.thebusinessresearchcompany.com/report/inactivated-influenza-vaccine-global-market-report
How Does The Inactivated Influenza Vaccine Market Perform Across Major Global Regions?
North America was the largest region in the inactivated influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Inactivated Influenza Vaccine Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24251&type=smp
Browse Through More Reports Similar to the Global Inactivated Influenza Vaccine Market 2026, By The Business Research Company
Ultraviolet Analyzer Market Report 2026
https://www.thebusinessresearchcompany.com/report/ultraviolet-analyzer-global-market-report
Molecular Spectroscopy Market Report 2026
https://www.thebusinessresearchcompany.com/report/molecular-spectroscopy-global-market-report
Process Spectroscopy Market Report 2026
https://www.thebusinessresearchcompany.com/report/process-spectroscopy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model